Blog Exposure – Inovio Pharma Closed Collaboration Deal with ApolloBio to Develop and Commercialize VGX-3100 in Greater China

Stock Monitor: Cara Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Inovio Pharma, Inc. (NASDAQ: INO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=INO as the Company’s latest news hit the wire. On March 20, 2018, the Company announced that it has closed the deal with ApolloBio Corp., providing the latter with exclusive right to develop, manufacture, and commercialize VGX-3100 within Greater China (mainland China, Hong Kong, Macao, Taiwan). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Cara Therapeutics, Inc. (NASDAQ: CARA), which also belongs to the Healthcare sector as the Company Inovio Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CARA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Inovio Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=INO

Deal Details

ApolloBio will make an upfront payment of approximately $23 million to Inovio. ApolloBio will also make potential future payments up to $20 million upon meeting certain milestones. Inovio is also entitled to receive double-digit tiered royalty payments on sales.
ApolloBio will fund all clinical development costs within the licensed territory and will pay Inovio. The agreement also provides for the potential inclusion of the Republic of Korea during the next three years.
ApolloBio has received all regulatory and Board’s approvals for the agreement.
This collaboration of VGX-3100 encompasses the treatment and/or prevention of precancerous human papillomavirus (HPV) infections and HPV-driven dysplasias (including cervical, vulvar, and anal precancers).

Agreement Strengthens and Expands Inovio’s Global Efforts to Develop VGX-3100

Dr. J. Joseph Kim, President and Chief Executive Officer of Inovio, stated that ApolloBio is an excellent partner that will provide significant capabilities and expertise relating to product development, the Chinese regulatory landscape, and the commercial market in China.

Dr. J. Joseph added that this agreement strengthens and expands Inovio’s global efforts to develop VGX-3100.

Agreement Initially Announced in 2017

Inovio and ApolloBio announced the collaboration deal in February 2017. Under the agreement, Inovio would receive $15 million in upfront and near-term payments comprising $3 million signing fee and a $12 million milestone upon lifting of the VGX-3100 phase-3 pre-initiation clinical hold by the FDA. Under a separate equity agreement, ApolloBio also invested in Inovio’s common stock.

In January 2018, the agreement was amended. Based on the new agreement, ApolloBio was required to make an upfront payment of $23 million (an increase from the previously announced amount of $15 million), along with potential future payments up to $20 million upon meeting certain milestones. As part of the new terms, the parties also agreed to terminate ApolloBio’s right to purchase Inovio’s stock.

About Human Papillomavirus and Cervical Dysplasia

HPV is the most common sexually transmitted infection and is the main cause of cervical cancer, which kills more than 250,000 women every year worldwide. Two types of HPV (HPV 16 and HPV 18) cause 70% of cervical cancer cases. Cervical dysplasia is a precancerous condition in which abnormal cell growth occurs on the surface lining of the cervix or endocervical canal, the opening between the uterus and the vagina. Strongly associated with sexually transmitted HPV infection, cervical dysplasia is most common in women under age 30 but can develop at any age.

Currently, there are no approved medical treatments for persistent HPV infection or cervical dysplasia. The primary treatment for high-grade cervical dysplasia is surgical excision of the pre-cancerous lesion and a margin of healthy cervical tissue.

About VGX-3100

VGX-3100 is Inovio’s DNA immunotherapy product designed to treat precancers caused by HPV. VGX-3100 is designed to work in vivo to activate functional, antigen-specific, CD8+ T cells to clear persistent HPV 16/18 infection and cause regression of precancerous cervical dysplasia. VGX-3100 is a first-in-class HPV-specific immunotherapy that targets the underlying cause of cervical dysplasia, providing an opportunity for women to reduce their risk of cervical cancer without undergoing an invasive surgical procedure.

About Inovio Pharmaceuticals, Inc.

Founded in 1983 and based in Plymouth Meeting, Pennsylvania, Inovio Pharma is a clinical-stage pharmaceutical company, revolutionizing the fight against cancer and infectious diseases. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

About ApolloBio Corp.

ApolloBio Corp. is a leading Chinese biopharmaceutical company dedicated to improving the lives of Chinese patients by licensing in the late-stage oncology new drugs and cell & gene therapeutic technologies into Greater China.

Stock Performance Snapshot

March 21, 2018 – At Wednesday’s closing bell, Inovio Pharma’s stock rose 2.00%, ending the trading session at $5.10.

Volume traded for the day: 816.27 thousand shares.

Stock performance in the last month – up 20.85%; previous three-month period – up 18.60%; and year-to-date – up 23.49%

After yesterday’s close, Inovio Pharma’s market cap was at $432.73 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 493867